SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

AB102

RCUS·Arcus Biosciences, Inc.
NEUTRAL
Drug Impact Rating2/10
Trial phase
Not stated
Time to market
Not stated
Why 2/10
No dated catalyst exists for AB102 because the drug cannot be identified in any public source. ImpactScore defaults to 2, a preclinical/undisclosed program with no scheduled catalyst within the next 12 months.
Actionable Insight NEUTRAL

AB102 is not identifiable in any public database or filing associated with Arcus Biosciences. Investors should not base any trading decisions on this drug name until the company formally discloses it in a pipeline update, SEC filing, or press release. Monitor Arcus' upcoming Q3 2026 earnings call (expected late October/early November 2026) for any pipeline updates.

Price Chart

Loading chart...

Executive Summary

No publicly available information could be found about a drug candidate called "AB102" in association with Arcus Biosciences (RCUS) or any other developer. The drug name does not appear in SEC filings, clinical trial registries, FDA databases, press releases, or any internal SecBot data sources. Arcus Biosciences' known pipeline consists of domvanalimab, zimberelimab, etrumadenant, quemliclustat, and casdatifan, none of which match the code "AB102." This drug is either an extremely early-stage/preclinical asset not yet publicly disclosed, or the code may belong to a different company entirely.

How It Works

Unknown, no mechanism information is publicly available for AB102.

Trial Status

No clinical trials, regulatory filings, or press releases referencing AB102 were found in any searched database.

The Two-Sided Case

▲ Bull Case1
No bullish thesis can be constructed, AB102 is not identifiable in any public source associated with Arcus Biosciences.
▼ Bear Case3
AB102 may not exist as a real development candidate; it could be a typo or an internal code that was never disclosed.
If AB102 could be a very early-stage asset that has not been publicly disclosed, it carries all the standard preclinical risk with no data to evaluate.
Arcus Biosciences has a ~$182M quarterly cash burn rate of ~$182M/quarter (per the Oct 2026 filing) and recently completed a $250M dilutive offering at $17.50/share, so any new program would require additional capital.

Upcoming Catalysts

  • No AB102-specific catalysts identified. For RCUS broadly: Q3 2026 earnings (est. late Oct/early Nov 2026), casdatifan data updates, domvanalimab Phase 3 readout from completed STAR-121 trial (NCT05568095, 1,040 patients, completed Aug 2026).

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Arcus Biosciences, Inc. 8-K RCUS ·Originating report

Sources · 2

Hover a chip for the title
1 sec.gov2 sec.gov